Developer docs
API playgroundTry for free, no card

Search company profiles

Anika Therapeutics

Full company profile

uuid0007czs

Namestring
Anika Therapeutics
Legal namestring
Anika Therapeutics, Inc.
Company typeenum
Public
Founded yearint
1992
Descriptiontext

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a Bedford, Massachusetts-based medical device company founded in 1992 that develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair, built on a proprietary hyaluronic acid (HA) technology platform with 30+ years of domain expertise. The company operates two product franchises: Regenerative Solutions (Integrity HA-based rotator cuff and tendon repair implant, Hyalofast cartilage regeneration scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation, and the RevoMotion Reverse Shoulder Arthroplasty System) and Osteoarthritis Pain Management (Cingal combination HA+steroid single injection, Monovisc single-injection HA viscosupplement, Orthovisc multi-injection HA viscosupplement). Products are available in 45+ countries worldwide.

Anika serves orthopedic surgeons, sports medicine physicians, and osteoarthritis patients through a dual-channel commercial model. The Commercial Channel uses direct enterprise field sales and physician engagement, targeting healthcare providers and growing 22% in Q4 2025 with 10%-20% projected growth for 2026. The OEM Channel supplies HA-based products to large medical device manufacturers (notably J&J MedTech) for incorporation into their portfolios, though this channel is under pricing pressure and declined 12% in Q4 2025. The company also markets to patients via a Find a Doctor locator tool and medical education content.

Anika monetizes through one-time product sales across both channels. FY2025 revenue was $112.8M (down 6% YoY), with Q1 2026 at $29.6M (up 13% YoY) and FY2026 guidance of $114M-$122.5M. Strategic priorities include advancing the Hyalofast PMA toward FDA approval, scaling the Integrity and RevoMotion product lines, restructuring costs (~$2.5M annualized adjusted EBITDA savings), and completing a $15M share repurchase program. The Arthrosurface joint preservation business was divested in October 2024 to refocus on core HA-based regenerative and OA pain management offerings.

Short descriptiontext

Anika Therapeutics (NASDAQ: ANIK) is a Bedford, MA-based medical device company that develops and commercializes hyaluronic acid-based regenerative and osteoarthritis pain management products for orthopedic surgeons, sports medicine physicians, and OA patients across 45+ countries, operating through direct sales and OEM channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid orthopedic products, regenerative orthopedic solutions, osteoarthritis pain management, viscosupplementation injections, cartilage repair scaffolds
Industry1 code
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - Commercial Channel
TypeOne Time License
Description

Direct sales of orthopedic regenerative solutions and osteoarthritis pain management products to healthcare providers and through distribution networks. Commercial Channel revenue was $13.3 million in Q4 2025, growing 22% year-over-year. Expected to grow 10%-20% in 2026.

finance.yahoo.com
2Product Sales - OEM Channel
TypeOne Time License
Description

Sales to original equipment manufacturer partners including J&J MedTech. OEM Channel faced 12% decline in Q4 2025 due to pricing pressures. The channel is expected to continue facing headwinds from J&J MedTech pricing pressures.

investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Integrity
Description

Rotator cuff and tendon repair augmentation implant system

anika.com
+6 more records
Core offering1 text field

Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on a proprietary hyaluronic acid (HA) technology platform for orthopedic tissue protection, healing, and repair. Its portfolio spans Regenerative Solutions (Integrity tendon repair implant, Hyalofast cartilage scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation) and Osteoarthritis Pain Management (Cingal, Monovisc, Orthovisc viscosupplements), supplemented by the RevoMotion Reverse Shoulder Arthroplasty System. Products are sold to orthopedic surgeons and healthcare providers via a Commercial direct sales channel and to large OEMs such as J&J MedTech via an OEM channel, distributed across 45+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Integrity product line revenue more than doubled in 2025 after receiving 510(k) clearance in 2023
+3 more records
Product overview1 text field

Anika Therapeutics offers a comprehensive portfolio of hyaluronic acid-based orthopedic products organized into two main categories: Regenerative Solutions and Osteoarthritis (OA) Pain Management. The Regenerative Solutions portfolio includes Integrity (hyaluronic acid implant for rotator cuff and tendon repair), Hyalofast (cartilage regeneration scaffold), Tactoset (injectable bone substitute), and NanoFx (advanced bone marrow stimulation). The OA Pain Management portfolio features Cingal (combination HA and steroid single injection), Monovisc (single-injection HA viscosupplement), and Orthovisc (multi-injection HA viscosupplement). The company also launched the RevoMotion Reverse Shoulder Arthroplasty System in February 2024. All products leverage the company's proprietary hyaluronic acid technology platform and are available in over 45 countries worldwide.

Product and service8 records
1Integrity
CategoryRegenerative Solutions
Description

Hyaluronic acid-based implant for rotator cuff and tendon repair augmentation. Enhances strength and biological support in rotator cuff repairs with demonstrated thickening of rotator cuff repair in postoperative imaging. For orthopedic surgeons performing rotator cuff and tendon repair procedures.

2Hyalofast
CategoryRegenerative Solutions
Description

Cartilage regeneration scaffold using hyaluronic acid technology for single-stage cartilage repair procedures. Completed Phase III FastTRACK clinical trial; PMA filing submitted to FDA in October 2025. For orthopedic surgeons treating patients with cartilage defects.

3Tactoset
CategoryRegenerative Solutions
Description

Injectable bone substitute product for orthopedic regenerative procedures. For orthopedic surgeons performing bone substitute / void filling procedures.

4NanoFx
CategoryRegenerative Solutions
Description

Advanced bone marrow stimulation product for orthopedic repair procedures. For orthopedic surgeons performing bone marrow stimulation techniques.

5Cingal
CategoryOsteoarthritis Pain Management
Description

Next generation combination hyaluronic acid and steroid single injection for osteoarthritis pain management, providing immediate pain relief lasting up to 6 months, reducing stiffness and improving function; helps postpone knee replacement surgery. For healthcare providers treating osteoarthritis pain.

6Monovisc
CategoryOsteoarthritis Pain Management
Description

Single-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.

7Orthovisc
CategoryOsteoarthritis Pain Management
Description

Multi-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.

8RevoMotion Reverse Shoulder Arthroplasty System
CategoryShoulder Arthroplasty
Description

Reverse shoulder arthroplasty system featuring the smallest diameter threaded baseplate on the market, targeting severe rotator cuff conditions. For orthopedic surgeons performing reverse shoulder arthroplasty.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-01
Description

J&J MedTech is a key OEM customer for Anika's viscosupplementation products through the OEM Channel. The relationship involves supply of HA-based products for J&J's osteoarthritis pain management offerings. However, J&J MedTech has been imposing pricing pressures on Anika, contributing to a 12% decline in the OEM Channel in Q4 2025 and ongoing headwinds in 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Seikagaku Corporation
TypeDirect peer
Description

Japanese specialty pharmaceutical company focused on hyaluronic acid-based products, including viscosupplements (Artz/SUPPARTZ) directly competing with Anika's Monovisc/Orthovisc/Cingal. Most direct comparable in HA technology platform and orthopedic pain management focus.

TypeDirect peer
Description

Orthopedic regenerative medicine company offering viscosupplements (Durolane, Gelsyn-3) and bone graft substitutes, directly competing with Anika in OA pain management and cartilage/bone repair categories. Similar mid-cap, single-therapeutic-focus profile.

TypeBroad incumbent
Description

Markets the Synvisc/Synvisc-One line of hyaluronic acid viscosupplements, directly competing with Anika's Monovisc/Orthovisc/Cingal in the OA pain management category. Operates as part of Sanofi's broader specialty care/consumer health portfolio.

TypeBroad incumbent
Description

Markets Euflexxa, a hyaluronic acid viscosupplement that directly competes with Anika's Monovisc and Orthovisc in the OA pain management space. Part of Ferring's broader specialty pharma portfolio.

TypeBroad incumbent
Description

Large diversified orthopedic medical device company with broad sports medicine and joint reconstruction portfolios. Competitor in shoulder/rotator cuff (where RevoMotion competes) and broader orthopedic surgical markets.

TypeBroad incumbent
Description

Global orthopedic medical device leader across joint reconstruction, sports medicine, and biologics. Competes with Anika in shoulder arthroplasty and regenerative/orthobiologics adjacencies through its broader portfolio.

TypeBroad incumbent
Description

Global medical device company with significant sports medicine and orthobiologics portfolios. Competes with Anika in cartilage repair and joint preservation, particularly relevant as Anika scales Hyalofast and Integrity.

TypeBroad incumbent
Description

Private orthopedic medical device leader in sports medicine and soft tissue repair. Direct competitor in rotator cuff repair augmentation (where Integrity competes) and cartilage restoration markets.

TypeOthers
Description

Both Anika's largest OEM customer (for HA viscosupplements) and a competitor in shoulder reconstruction and sports medicine through DePuy Synthes/Mitek. Pricing pressure from this partner is a current headwind to Anika's OEM channel.

TypeEmerging player
Description

Mid-cap orthopedic and sports medicine company with a growing portfolio in rotator cuff repair, cartilage restoration, and biologics. Competes with Anika in similar surgical specialties with comparable commercial sales force scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anika Therapeutics

Orthopedic Medical Devicesanikatherapeutics.com

Anika Therapeutics (NASDAQ: ANIK) is a Bedford, MA-based medical device company that develops and commercializes hyaluronic acid-based regenerative and osteoarthritis pain management products for orthopedic surgeons, sports medicine physicians, and OA patients across 45+ countries, operating through direct sales and OEM channels.

What Anika Therapeutics does

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a Bedford, Massachusetts-based medical device company founded in 1992 that develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair, built on a proprietary hyaluronic acid (HA) technology platform with 30+ years of domain expertise. The company operates two product franchises: Regenerative Solutions (Integrity HA-based rotator cuff and tendon repair implant, Hyalofast cartilage regeneration scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation, and the RevoMotion Reverse Shoulder Arthroplasty System) and Osteoarthritis Pain Management (Cingal combination HA+steroid single injection, Monovisc single-injection HA viscosupplement, Orthovisc multi-injection HA viscosupplement). Products are available in 45+ countries worldwide.

Anika serves orthopedic surgeons, sports medicine physicians, and osteoarthritis patients through a dual-channel commercial model. The Commercial Channel uses direct enterprise field sales and physician engagement, targeting healthcare providers and growing 22% in Q4 2025 with 10%-20% projected growth for 2026. The OEM Channel supplies HA-based products to large medical device manufacturers (notably J&J MedTech) for incorporation into their portfolios, though this channel is under pricing pressure and declined 12% in Q4 2025. The company also markets to patients via a Find a Doctor locator tool and medical education content.

Anika monetizes through one-time product sales across both channels. FY2025 revenue was $112.8M (down 6% YoY), with Q1 2026 at $29.6M (up 13% YoY) and FY2026 guidance of $114M-$122.5M. Strategic priorities include advancing the Hyalofast PMA toward FDA approval, scaling the Integrity and RevoMotion product lines, restructuring costs (~$2.5M annualized adjusted EBITDA savings), and completing a $15M share repurchase program. The Arthrosurface joint preservation business was divested in October 2024 to refocus on core HA-based regenerative and OA pain management offerings.

Anika Therapeutics firmographics

Firmographics
Name
Anika Therapeutics
Legal name
Anika Therapeutics, Inc.
Website
https://anikatherapeutics.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
251–500 employees
Short description
Anika Therapeutics (NASDAQ: ANIK) is a Bedford, MA-based medical device company that develops and commercializes hyaluronic acid-based regenerative and osteoarthritis pain management products for orthopedic surgeons, sports medicine physicians, and OA patients across 45+ countries, operating through direct sales and OEM channels.
Ownership category
akta.pro rank

Anika Therapeutics industry classification

Industry
Product category
Orthopedic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Hyaluronic acid orthopedic products
  • Regenerative orthopedic solutions
  • Osteoarthritis pain management
  • Viscosupplementation injections
  • Cartilage repair scaffolds

Where Anika Therapeutics is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Anika Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - Commercial Channel: Direct sales of orthopedic regenerative solutions and osteoarthritis pain management products to healthcare providers and through distribution networks. Commercial Channel revenue was $13.3 million in Q4 2025, growing 22% year-over-year. Expected to grow 10%-20% in 2026.
  2. Product Sales - OEM Channel: Sales to original equipment manufacturer partners including J&J MedTech. OEM Channel faced 12% decline in Q4 2025 due to pricing pressures. The channel is expected to continue facing headwinds from J&J MedTech pricing pressures.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Anika Therapeutics product offering

Product offering

Core offering

Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on a proprietary hyaluronic acid (HA) technology platform for orthopedic tissue protection, healing, and repair. Its portfolio spans Regenerative Solutions (Integrity tendon repair implant, Hyalofast cartilage scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation) and Osteoarthritis Pain Management (Cingal, Monovisc, Orthovisc viscosupplements), supplemented by the RevoMotion Reverse Shoulder Arthroplasty System. Products are sold to orthopedic surgeons and healthcare providers via a Commercial direct sales channel and to large OEMs such as J&J MedTech via an OEM channel, distributed across 45+ countries.

Product overview

Anika Therapeutics offers a comprehensive portfolio of hyaluronic acid-based orthopedic products organized into two main categories: Regenerative Solutions and Osteoarthritis (OA) Pain Management. The Regenerative Solutions portfolio includes Integrity (hyaluronic acid implant for rotator cuff and tendon repair), Hyalofast (cartilage regeneration scaffold), Tactoset (injectable bone substitute), and NanoFx (advanced bone marrow stimulation). The OA Pain Management portfolio features Cingal (combination HA and steroid single injection), Monovisc (single-injection HA viscosupplement), and Orthovisc (multi-injection HA viscosupplement). The company also launched the RevoMotion Reverse Shoulder Arthroplasty System in February 2024. All products leverage the company's proprietary hyaluronic acid technology platform and are available in over 45 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Integrity: Rotator cuff and tendon repair augmentation implant system
  • Hyalofast
  • Tactoset
  • NanoFx
  • Cingal
  • Monovisc
  • Orthovisc

Products and services

  • Integrity Hyaluronic acid-based implant for rotator cuff and tendon repair augmentation. Enhances strength and biological support in rotator cuff repairs with demonstrated thickening of rotator cuff repair in postoperative imaging. For orthopedic surgeons performing rotator cuff and tendon repair procedures.
  • Hyalofast Cartilage regeneration scaffold using hyaluronic acid technology for single-stage cartilage repair procedures. Completed Phase III FastTRACK clinical trial; PMA filing submitted to FDA in October 2025. For orthopedic surgeons treating patients with cartilage defects.
  • Tactoset Injectable bone substitute product for orthopedic regenerative procedures. For orthopedic surgeons performing bone substitute / void filling procedures.
  • NanoFx Advanced bone marrow stimulation product for orthopedic repair procedures. For orthopedic surgeons performing bone marrow stimulation techniques.
  • Cingal Next generation combination hyaluronic acid and steroid single injection for osteoarthritis pain management, providing immediate pain relief lasting up to 6 months, reducing stiffness and improving function; helps postpone knee replacement surgery. For healthcare providers treating osteoarthritis pain.
  • Monovisc Single-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.
  • Orthovisc Multi-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.
  • RevoMotion Reverse Shoulder Arthroplasty System Reverse shoulder arthroplasty system featuring the smallest diameter threaded baseplate on the market, targeting severe rotator cuff conditions. For orthopedic surgeons performing reverse shoulder arthroplasty.

Quantifiable outcome

  • Integrity product line revenue more than doubled in 2025 after receiving 510(k) clearance in 2023
  • +3 more outcomes

Companies that use Anika Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Anika Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Anika Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Johnson & Johnson MedTechcoreChannel Partner/ Reseller/ Distributor · 1 July 2025J&J MedTech is a key OEM customer for Anika's viscosupplementation products through the OEM Channel. The relationship involves supply of HA-based products for J&J's osteoarthritis pain management offerings. However, J&J MedTech has been imposing pricing pressures on Anika, contributing to a 12% decline in the OEM Channel in Q4 2025 and ongoing headwinds in 2026.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Anika Therapeutics competitors and assessment

Company assessment

Direct peers

  • Seikagaku Corporation: Japanese specialty pharmaceutical company focused on hyaluronic acid-based products, including viscosupplements (Artz/SUPPARTZ) directly competing with Anika's Monovisc/Orthovisc/Cingal. Most direct comparable in HA technology platform and orthopedic pain management focus.
  • Bioventus: Orthopedic regenerative medicine company offering viscosupplements (Durolane, Gelsyn-3) and bone graft substitutes, directly competing with Anika in OA pain management and cartilage/bone repair categories. Similar mid-cap, single-therapeutic-focus profile.

Broad incumbents

  • Sanofi (CHC/Synvisc franchise): Markets the Synvisc/Synvisc-One line of hyaluronic acid viscosupplements, directly competing with Anika's Monovisc/Orthovisc/Cingal in the OA pain management category. Operates as part of Sanofi's broader specialty care/consumer health portfolio.
  • Ferring Pharmaceuticals: Markets Euflexxa, a hyaluronic acid viscosupplement that directly competes with Anika's Monovisc and Orthovisc in the OA pain management space. Part of Ferring's broader specialty pharma portfolio.
  • Stryker Corporation: Large diversified orthopedic medical device company with broad sports medicine and joint reconstruction portfolios. Competitor in shoulder/rotator cuff (where RevoMotion competes) and broader orthopedic surgical markets.
  • Zimmer Biomet: Global orthopedic medical device leader across joint reconstruction, sports medicine, and biologics. Competes with Anika in shoulder arthroplasty and regenerative/orthobiologics adjacencies through its broader portfolio.
  • Smith+Nephew: Global medical device company with significant sports medicine and orthobiologics portfolios. Competes with Anika in cartilage repair and joint preservation, particularly relevant as Anika scales Hyalofast and Integrity.
  • Arthrex: Private orthopedic medical device leader in sports medicine and soft tissue repair. Direct competitor in rotator cuff repair augmentation (where Integrity competes) and cartilage restoration markets.

Others

  • Johnson & Johnson MedTech (DePuy Synthes): Both Anika's largest OEM customer (for HA viscosupplements) and a competitor in shoulder reconstruction and sports medicine through DePuy Synthes/Mitek. Pricing pressure from this partner is a current headwind to Anika's OEM channel.

Emerging players

  • CONMED Corporation: Mid-cap orthopedic and sports medicine company with a growing portfolio in rotator cuff repair, cartilage restoration, and biologics. Competes with Anika in similar surgical specialties with comparable commercial sales force scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Anika Therapeutics social profiles

Digital presence

Anika Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anika Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Anika Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anika Therapeutics M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anika Therapeutics

What does Anika Therapeutics do?

Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on a proprietary hyaluronic acid (HA) technology platform for orthopedic tissue protection, healing, and repair. Its portfolio spans Regenerative Solutions (Integrity tendon repair implant, Hyalofast cartilage scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation) and Osteoarthritis Pain Management (Cingal, Monovisc, Orthovisc viscosupplements), supplemented by the RevoMotion Reverse Shoulder Arthroplasty System. Products are sold to orthopedic surgeons and healthcare providers via a Commercial direct sales channel and to large OEMs such as J&J MedTech via an OEM channel, distributed across 45+ countries.

Is Anika Therapeutics a public or private company?

Anika Therapeutics is a public company. It is classified as public and is currently operating.

When was Anika Therapeutics founded?

Anika Therapeutics was founded in 1992. It employs 251 to 500 people.

Where is Anika Therapeutics based?

Anika Therapeutics is headquartered in Bedford, United States, in the North America region.

How does Anika Therapeutics make money?

Two revenue lines are on record. Product Sales - Commercial Channel is the primary driver. The others are product Sales - OEM Channel.

Who are Anika Therapeutics's main competitors?

Direct peers on record are Seikagaku Corporation and Bioventus. Broad incumbents are Sanofi (CHC/Synvisc franchise), Ferring Pharmaceuticals, Stryker Corporation, Zimmer Biomet, Smith+Nephew and Arthrex. Johnson & Johnson MedTech (DePuy Synthes) is listed as an others. CONMED Corporation is listed as an emerging player.

Does Anika Therapeutics have an API?

No public API is recorded for Anika Therapeutics.

What industry is Anika Therapeutics in?

Anika Therapeutics's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAnalyzing AbCellera Biologics (NASDAQ:ABCL) & Anika Therapeutics (NASDAQ:ANIK)Anika Therapeutics and AbCellera Biologics are compared on profitability, valuation, and analyst ratings. Anika beats AbCellera on 9 of 15 factors, with higher revenue, lower P/E, and a 51% upside versus 26% for AbCellera. Analysts favor Anika's lower volatility and stronger institutional ownership.Quiver Quantitative$ANIK stock is down 22% today. Here's what we see in our data. | ANIK Stock NewsANIK stock fell 22% today with $2,087,395 in trading volume. Insiders made two purchases totaling $41,060, while 60 institutional investors added shares and 58 reduced positions in Q2 2026, including AQR Capital's large addition and Morgan Stanley's reduction.Seeking AlphaAnika projects 6%-10% 2026 revenue growth while targeting 15%-17% adjusted EBITDA margin (NASDAQ:ANIK)Anika Therapeutics reported Q3 2026 revenue of $30.6 million, up 10% year-over-year, with commercial channel revenue reaching a record $14 million. The company raised its 2026 revenue growth guidance to 6%-10% and adjusted EBITDA margin to 15%-17%, while noting a new Boehringer Hyvisc agreement and FDA rejection of its Hyalofast PMA.TradingViewAnika Therapeutics Q3 2026 Earnings Call Is LiveAnika Therapeutics' Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. The call may include surprise news, and management commentary on future demand, margins, or capital spending could move markets.Quiver QuantitativeANIKA THERAPEUTICS ($ANIK) Releases Q3 2026 Earnings | ANIK Stock NewsAnika Therapeutics reported Q3 2026 earnings of $0.29 per share, beating estimates of $0.06, and revenue of $30.59 million, up from $30.02 million. Insiders made two purchases in the past six months, while 61 institutional investors added shares and 59 reduced positions in the most recent quarter.TradingViewAnika Therapeutics Reports 10% Revenue Growth, Raises 2026 GuidanceAnika Therapeutics reported Q3 2026 revenue of $30.6 million, up 10% year over year, with a gross margin of 62%. The company raised its 2026 revenue growth guidance to 6-10% and adjusted EBITDA margin outlook to 15-17%. It also entered a new Hyvisc distribution partnership and completed Cingal bioequivalence study enrollment.MarketBeatAnika Therapeutics (ANIK) Expected to Post Earnings on FridayAnika Therapeutics is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting $0.42 EPS and $29.44 million revenue. The company previously beat estimates with $0.42 EPS and $32.61 million revenue. Analysts have an average price target of $22.00.American Banking and Market NewsAnika Therapeutics (ANIK) Set to Announce Earnings on FridayAnika Therapeutics is set to report Q3 2026 earnings on Friday, November 6th, with analysts expecting EPS of $0.42 and revenue of $29.44 million. The company previously beat estimates with EPS of $0.42 and revenue of $32.61 million. Analysts have a consensus 'Hold' rating with a price target of $22.00.American Banking and Market NewsCritical Comparison: Anika Therapeutics (NASDAQ:ANIK) and ADMA Biologics (NASDAQ:ADMA)ADMA Biologics outperforms Anika Therapeutics on 12 of 14 comparison factors, including higher revenue, earnings, and profitability. Analysts rate ADMA Biologics more favorably with a higher consensus price target and greater upside potential.Defense WorldAnika Therapeutics (NASDAQ:ANIK) Cut to Hold at Zacks ResearchZacks Research lowered Anika Therapeutics from a strong-buy to a hold rating. The stock opened at $19.66, with a consensus rating of Hold and an average price target of $22.00. Analysts forecast 0.14 EPS for the current year.